219 related articles for article (PubMed ID: 24635062)
1. Increased ratio of FoxP3+ regulatory T cells/CD3+ T cells in skin lesions in drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms.
Morito H; Ogawa K; Fukumoto T; Kobayashi N; Morii T; Kasai T; Nonomura A; Kishimoto T; Asada H
Clin Exp Dermatol; 2014 Apr; 39(3):284-91. PubMed ID: 24635062
[TBL] [Abstract][Full Text] [Related]
2. Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response.
Fondi C; Nozzoli C; Benemei S; Baroni G; Saccardi R; Guidi S; Nicoletti P; Bartolozzi B; Pimpinelli N; Santucci M; Bosi A; Massi D
Biol Blood Marrow Transplant; 2009 Aug; 15(8):938-47. PubMed ID: 19589483
[TBL] [Abstract][Full Text] [Related]
3. The predominant drug-specific T-cell population may switch from cytotoxic T cells to regulatory T cells during the course of anticonvulsant-induced hypersensitivity.
Hanafusa T; Azukizawa H; Matsumura S; Katayama I
J Dermatol Sci; 2012 Mar; 65(3):213-9. PubMed ID: 22226608
[TBL] [Abstract][Full Text] [Related]
4. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
5. Drug rash with eosinophilia and systemic symptoms and graft-versus-host disease developing sequentially in a patient.
Natkunarajah J; Watson K; Diaz-Cano S; Mufti G; du Vivier A; Creamer D
Clin Exp Dermatol; 2009 Mar; 34(2):199-201. PubMed ID: 18793307
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms.
Takehara A; Aoyama Y; Kurosawa M; Shirafuji Y; Umemura H; Kamiya K; Ushigome Y; Kano Y; Shiohara T; Iwatsuki K
Br J Dermatol; 2016 Nov; 175(5):944-952. PubMed ID: 27087170
[TBL] [Abstract][Full Text] [Related]
7. Stevens-Johnson syndrome and toxic epidermal necrolysis due to anticonvulsants share certain clinical and laboratory features with drug-induced hypersensitivity syndrome, despite differences in cutaneous presentations.
Teraki Y; Shibuya M; Izaki S
Clin Exp Dermatol; 2010 Oct; 35(7):723-8. PubMed ID: 19874350
[TBL] [Abstract][Full Text] [Related]
8. Drug reaction with eosinophilia and systemic symptoms: is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases.
Walsh S; Diaz-Cano S; Higgins E; Morris-Jones R; Bashir S; Bernal W; Creamer D
Br J Dermatol; 2013 Feb; 168(2):391-401. PubMed ID: 23034060
[TBL] [Abstract][Full Text] [Related]
9. Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS).
Miyagawa F; Asada H
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670052
[TBL] [Abstract][Full Text] [Related]
10. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR).
Kano Y; Tohyama M; Aihara M; Matsukura S; Watanabe H; Sueki H; Iijima M; Morita E; Niihara H; Asada H; Kabashima K; Azukizawa H; Hashizume H; Nagao K; Takahashi H; Abe R; Sotozono C; Kurosawa M; Aoyama Y; Chu CY; Chung WH; Shiohara T
J Dermatol; 2015 Mar; 42(3):276-82. PubMed ID: 25623158
[TBL] [Abstract][Full Text] [Related]
11. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption.
Kano Y; Hirahara K; Mitsuyama Y; Takahashi R; Shiohara T
Allergy; 2007 Dec; 62(12):1439-44. PubMed ID: 17983378
[TBL] [Abstract][Full Text] [Related]
12. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
13. Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study.
Ortonne N; Valeyrie-Allanore L; Bastuji-Garin S; Wechsler J; de Feraudy S; Duong TA; Delfau-Larue MH; Chosidow O; Wolkenstein P; Roujeau JC
Br J Dermatol; 2015 Jul; 173(1):50-8. PubMed ID: 25630796
[TBL] [Abstract][Full Text] [Related]
14. Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions.
Ushigome Y; Mizukawa Y; Kimishima M; Yamazaki Y; Takahashi R; Kano Y; Shiohara T
Clin Exp Allergy; 2018 Nov; 48(11):1453-1463. PubMed ID: 30112775
[TBL] [Abstract][Full Text] [Related]
15. CD3+/Tregs ratio in donor grafts is linked to acute graft-versus-host disease and immunologic recovery after allogeneic peripheral blood stem cell transplantation.
Pastore D; Delia M; Mestice A; Carluccio P; Perrone T; Gaudio F; Curci P; Rossi AR; Ricco A; Specchia G
Biol Blood Marrow Transplant; 2012 Jun; 18(6):887-93. PubMed ID: 22062803
[TBL] [Abstract][Full Text] [Related]
16. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution.
Ushigome Y; Kano Y; Ishida T; Hirahara K; Shiohara T
J Am Acad Dermatol; 2013 May; 68(5):721-8. PubMed ID: 23182063
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease.
Kawakami T; Fujita A; Takeuchi S; Muto S; Soma Y
J Am Acad Dermatol; 2009 Jan; 60(1):146-9. PubMed ID: 19103366
[TBL] [Abstract][Full Text] [Related]
18. Severe graft-versus-host disease-like enterocolitis accompanied with cytomegalovirus-reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
Takamiyagi S; Iriki H; Asahina Y; Furuichi Y; Funakoshi T; Ichikawa M; Mikami Y; Okita H; Sakiyama T; Inazumi T; Amagai M; Takahashi H
J Dermatol; 2022 Aug; 49(8):796-799. PubMed ID: 35502510
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of human herpes virus 6 receptor CD134/OX40 in skin lesions of patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
Lee ES; Kiuchi Y; Inomata N; Sueki H
J Dermatol; 2023 Mar; 50(3):387-392. PubMed ID: 36121111
[TBL] [Abstract][Full Text] [Related]
20. Occupational trichloroethylene hypersensitivity syndrome: human herpesvirus 6 reactivation and rash phenotypes.
Kamijima M; Wang H; Yamanoshita O; Ito Y; Xia L; Yanagiba Y; Chen C; Okamura A; Huang Z; Qiu X; Song X; Cai T; Liu L; Ge Y; Deng Y; Naito H; Yoshikawa T; Tohyama M; Li L; Huang H; Nakajima T
J Dermatol Sci; 2013 Dec; 72(3):218-24. PubMed ID: 23928230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
